Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

Table 3 Bowel Habit Survey

Variables	Baseline to week 4		Baseline to week 12
	Improvement rate	P-value	Improvement rate	P-value
Decrease in stool frequency among those reporting change	18/28 (64.3%)	0.13	18/32 (56.3%)	0.48
Improved stool consistency among those reporting change	23/30 (76.75%)	0.004	19/27 (70.4%)	0.03
Decrease in stool volume among those reporting change	11/16 (68.8%)	0.13	8/13 (61.5%)	0.41
Resolution of blood in stool among those reporting change	5/6 (83.3%)	0.10	4/6 (66.7%)	0.41
	Baseline to week 4 (n = 70)		Baseline to week 12 (n = 62)
Overall change in bowel habit score (BHS) [mean (SD)]	-0.281 ± 0.719	0.002	-0.227 ± 0.707	0.01

Self-reported bowel habit score (BHS) was assessed on a scale in which stool consistency was (solid = 1, loose = 3, watery = 5); volume (small = 1, moderate = 3, large = 5), blood (no = 1, yes = 5); Frequency (1 - 5). For example, a subject with baseline responses of: Solid, Moderate, no blood, and frequency of "2" would have a score of: (1 + 3 + 1 + 2)/4 = 1.75 for their baseline summary score. Therefore the scale has a minimum of 1 (best BHS outcome) and a maximum of 5 (worst BHS outcome); SD, standard deviation.

ISSN: 1742-6405